Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.

Current oncology (Toronto, Ont.) - 12 Jul 2026

Cheung Verna, Davidson Marta, Atenafu Eshetu G, Arruda Andrea, Claudio Jaime O, Bankar Aniket, Maze Dawn, Gupta Vikas, Sibai Hassan

Abstract excerpt

The prognostic significance of myelodysplasia-related gene mutations (MDS-RGMs), defined by the ELN 2022 classification and Mutation-Enhanced International Prognostic Score System high-risk mutations (MIPSS70-HRM), in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs) remains unclear. We conducted a retrospective study of 101 AP/BP MPN patients with intermediate-risk cytogenetics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to ELN gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TP53 gene

Share to Karyotype

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42505221
DOI: 10.3390/curroncol33070419
PMCID: PMC13408622

Genes

TP53
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.PMID 42505221Read ↗

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomesSemantic proximity Read ↗

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.Semantic proximity Read ↗

Accelerated Phase of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.Semantic proximity Read ↗

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM studySemantic proximity Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].Semantic proximity Read ↗

Accelerated and Blast Phase Myeloproliferative Neoplasms.Semantic proximity Read ↗

Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.Semantic proximity Read ↗

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.